Sobi is an international specialty healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients.

 Sobi has been involved
in the development and
manufacturing of
recombinant protein drugs
since the technology was first
developed more than
30 years ago.

 We want to make a difference
to people with rare diseases.

By working closely
with patients and their relatives
we learn about their daily
challenges and needs.


Sobi has a diversified and growth-oriented commercial product portfolio within three business lines.
To products

World Hemophilia Day 2016

Annual General Meeting 2016

The Annual General Meeting in Swedish Orphan Biovitrum AB (publ), Reg. No. 556038-9321, was held on Tuesday, May 24, 2016 at 3.00 p.m. at the Royal Swedish Academy of Engineering Sciences (IVA), Grev Turegatan 16, Stockholm, Sweden.
Read more

Presentation of Sobi's Interim Report January - March 2016

27 April, 2016 - Revenues for the quarter totalled SEK 1,273 M (865), an increase of 47 per cent.

Share Price


Volume: 1,432,943
Ticker: SOBI
SSE Large

Opouštíte webové stránky SOBI

Společnost SOBI již dále nenese odpovědnost za obsah ani funkčnost internetových stránek jiných subjektů.

Přejete si opustit stránky?

Ano    Ne